The future of drug eluting stents [PDF]
Heart, 2005 In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation.
Anis, RR, Karsch, KR
openaire +3 more sources
A polymer coated cicaprost-eluting stent increases neointima formation and impairs vessel function in the rabbit iliac artery [PDF]
, 2016 Drug-eluting stents have been successful in reducing in-stent restenosis but are not suitable for all lesion types and have been implicated in causing late stent thrombosis due to incomplete regeneration of the endothelial cell layer.
Jones, Robert L. +4 more
core +2 more sources
An Analysis of Cost-Effectiveness of Stents Used in the Treatment of Coronary Artery Disease
Balkan Medical Journal, 2019 Background: There is only limited information about the cost-effectiveness of drug-eluting stents compared with bare-metal stents in Turkey. Aims: To evaluate bare-metal and drug-eluting stents used in the treatment of coronary artery disease from the ...
Ferda Işıkçelik +2 more
doaj +1 more source
Coronary Artery Disease, 2019 Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES.A total of 172 ...
Wang, Guozhong +5 more
openaire +3 more sources
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +3 more sources
Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention. [PDF]
, 2014 Cardiovascular disease remains one of the largest contributors to death worldwide. Improvements in cardiovascular technology leading to the current generation of drug-eluting stents, bioresorbable stents, and drug-eluting balloons, coupled with advances ...
Panitch, Alyssa, Scott, Rebecca A
core +2 more sources
Outcomes of supraflex Sirolimus-eluting coronary stents
Current Medical Issues, 2022 Background: The development of a sirolimus-eluting coronary stent (SES) was a big step forward in interventional cardiology. SES has been demonstrated in large, randomized clinical studies to reduce angiographic restenosis and target vessel ...
Vishal Virendra Singh +2 more
doaj +1 more source
The Drug-Eluting Stent Saga [PDF]
Circulation, 2009 Drug-eluting stents (DES) represent a breakthrough technology owing to their potent reduction of restenosis, which is a nuisance in the quality of life of affected patients, a rare cause of myocardial infarction (MI), and the principal shortcoming of stents compared with coronary artery bypass surgery.
Windecker, Stephan, Jüni, Peter
openaire +1 more source
Introductory editorial: drug-eluting stents or drug-eluting grafts? Insights from proteomic analysis [PDF]
, 2017 No abstract ...
Al-Attar, Nawwar +5 more
core +1 more source
Comportamiento mecánico ante la sobrexpansión de stents de cromo-cobalto comparados con stents de acero inoxidable, implantados en la aorta abdominal de conejos hipercolesterolémicos [PDF]
, 2018 Introducción: La fisiopatología de la disfunción diastólica del ventrículo izquierdo incluye alteraciones de la relajación ventricular, rigidez elástica pasiva o una combinación de ambos mecanismos.
Berrocal, Daniel +5 more
core +1 more source